The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

被引：0
|
作者：
Weber, Martin [1 ,2 ,3 ]
Kappos, Ludwig [4 ]
Hauser, Stephen [5 ]
Nicholas, Jacqueline [6 ]
Schneble, Hans-Martin [7 ]
Wang, Qing [7 ]
Giovannoni, Gavin [8 ]
Filippi, Massimo [9 ,10 ]
机构：
[1] Inst Neuropathol, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Gottingen, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Gottingen, Germany
[4] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[5] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA USA
[6] OhioHlth Multiple Sclerosis Clin, Columbus, OH USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Queen Mary Univ London, London, England
[9] IRCCS San Raffaele Sci Inst, Neurol Unit, Neurophysiol Serv, Neurorehabil Unit,Neuroimaging Res Unit,Div Neuro, Milan, Italy
[10] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P302/406
引用
收藏
页码：350 / 351
页数：2
相关论文
共 50 条
  • [21] Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
    Giovannoni, G.
    Kappos, L.
    Hauser, S. L.
    Montalban, X.
    Koendgen, H.
    Prajapati, K.
    Manfrini, M.
    Mehta, L.
    Wolinsky, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [22] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
    Fox, Edward J.
    Markowitz, Clyde
    Applebee, Angela
    Montalban, Xavier
    Wolinsky, Jerry S.
    Belachew, Sihbeshih
    Fiore, Damian
    Pei, Jinglan
    Musch, Bruno
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870
  • [23] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
    Kappos, L.
    Li, D.
    Calabresi, P.
    O'Connor, P.
    Bar-Or, A.
    Barkhof, F.
    Wells, C.
    Leppert, D.
    Glanzman, R.
    Tinbergen, J.
    Hauser, S.
    JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
  • [24] Treatment of Multiple Sclerosis with Ocrelizumab and Rituximab: value of long-term immunological monitoring for assesing the risk of infections and treatment response
    Torres Iglesias, Gabriel
    Martinez Feito, Ana
    Otero, Laura
    Lopez Molina, MariPaz
    Puertas Munoz, Inmaculada
    Suham Gonzalez, Andrea
    Geraldine Rita, Claudia
    Fernandez-Fournier, Mireya
    Chamorro, Beatriz
    Tallon, Antonio
    Lopez Granados, Eduardo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 336 - 336
  • [25] Long-Term Reduction in 48-Week Confirmed Disability Progresssion After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis
    Hauser, Stephen L.
    Kappos, Ludwig
    Montalban, Xavier
    Bar-Or, Amit
    Giovannoni, Gavin
    Model, Fabian
    Hubeaux, Stanislas
    Mehta, Lahar
    Wolinsky, Jerry S.
    NEUROLOGY, 2019, 92 (15)
  • [26] Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
    Hauser, S. L.
    Kappos, L.
    Montalban, X.
    Bar-or, A.
    Giovannoni, G.
    Model, F.
    Hubeaux, S.
    Mehta, L.
    Wolinsky, J. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 496 - 496
  • [27] Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis
    Giovannoni, Gavin
    Kappos, Ludwig
    de Seze, Jerome
    Hauser, Stephen
    Overell, James
    Koendgen, Harold
    Prajapati, Kalpesh
    Manfrini, Marianna
    Wang, Qing
    Wolinsky, Jerry
    NEUROLOGY, 2020, 94 (15)
  • [28] Long-Term Treatment with Intrathecal Baclofen in a Multiple Sclerosis Patient - a Case Report
    Stetkarova, Ivana
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2013, 76 : 15 - 17
  • [29] Inflammatory vaginitis associated with long-term rituximab treatment in a patient with multiple sclerosis
    Filikci, Zuhal
    Jensen, Rikke Marie
    Thorup Sellebjerg, Finn
    BMJ CASE REPORTS, 2022, 15 (11)
  • [30] Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies
    Cree, Bruce A. C.
    Pradhan, Ashish
    Pei, Jinglan
    Williams, Mitzi J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
12345